Diabetic Polyneuropathy Patients Exhibit an Altered Skeletal Muscle Proteome Phenotype
PROTEOMICS – Clinical Applications · 2026
DOI: 10.1002/prca.70060 ↗At a glance
Journal article in PROTEOMICS – Clinical Applications, 2026. Written by Frederik Forsberg Thybo and 5 co-authors. Institution: Department of Biomedicine, Aarhus University, Aarhus, Denmark. Major MEDLINE topics: Muscle, Skeletal, Diabetic Neuropathies, Proteome, Proteomics. 85 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Novo Nordisk Foundation Challenge Program, John and Birthe Meyer Foundation and Novo Nordisk Foundation Challenge.
Abstract (original language)
Purpose
Diabetic polyneuropathy (DPN) is a debilitating complication of diabetes that affects motor nerves and may impair skeletal muscle health. This study investigated skeletal muscle proteomic alterations associated with DPN compared with type 2 diabetes without DPN (T2D) and healthy controls (CON). Experimental Design An exploratory proteomic profiling was performed in 15 participants divided into three groups based on clinical and neurophysiological diagnosis (DPN, n = 5; T2D, n = 5; CON, n = 5). Biopsies from the gastrocnemius lateralis muscle were analyzed using LC‐MS/MS–based proteomics and pathway enrichment analyses.
Results
A total of 265 and 444 proteins were differentially expressed in DPN compared with T2D and CON, respectively (q < 0.05). Enrichment analyses revealed marked alterations in mitochondrial‐related pathways, including cellular respiration, distinguishing DPN from both comparison groups. Differences between T2D and CON were present but less pronounced. DPN was characterized by downregulation of glycogen‐regulating proteins (phosphorylase kinase G1 and A1) and upregulation of ferritin light chain (FTL), alpha actin 2, and myosin‐binding protein H. Conclusions and clinical relevance DPN is associated with a distinct and progressive skeletal muscle proteomic phenotype, supporting mitochondrial dysfunction as a key feature and providing a basis for future mechanistic and therapeutic studies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biomedicine, Aarhus University, Aarhus, Denmark.
- Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
- Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
- NMD Pharma A/S, Aarhus, Denmark.
- Exercise Biology, Department of Public Health, Aarhus University, Aarhus, Denmark.
- Research Unit for Molecular Medicine, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
ORCID profiles: Frederik Forsberg Thybo, Jesper Emil Jakobsgaard, Kristian Vissing, Johan Palmfeldt
Funding
- Novo Nordisk Foundation Challenge Program
- John and Birthe Meyer Foundation and Novo Nordisk Foundation Challenge
Cite
APA
Thybo, F. F., Khan, K. S., Jakobsgaard, J. E., Andersen, H., Vissing, K., & Palmfeldt, J. (2026). Diabetic Polyneuropathy Patients Exhibit an Altered Skeletal Muscle Proteome Phenotype. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.70060
Vancouver
Thybo FF, Khan KS, Jakobsgaard JE, Andersen H, Vissing K, Palmfeldt J. Diabetic Polyneuropathy Patients Exhibit an Altered Skeletal Muscle Proteome Phenotype. PROTEOMICS – Clinical Applications. 2026. doi:10.1002/prca.70060
BibTeX
@article{Thybo2026,
author = {Thybo, Frederik Forsberg and Khan, Karolina Snopek and Jakobsgaard, Jesper Emil and Andersen, Henning and Vissing, Kristian and Palmfeldt, Johan},
title = {Diabetic Polyneuropathy Patients Exhibit an Altered Skeletal Muscle Proteome Phenotype},
journal = {PROTEOMICS – Clinical Applications},
year = {2026},
doi = {10.1002/prca.70060}
}
EUVIMED